Liangxue Jiedu Runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: A double-blind randomized controlled trial

Introduction: Psoriasis is a kind of chronic inflammatory skin disease characterized by erythema, skin hyperplasia, scales and keratinocyte hyperproliferation. Psoriasis Vulgaris, the most common kind of psoriasis, severely deteriorates the life quality of patients. Traditional Chinese Medicine (TCM) is a good choice for the treatment of psoriasis, which has been proved to be safe and effective, and may reduce the recurrence rate. In clinical practice, Liangxue Jiedu Runzhi (LJR) ointment can effectively treat mild and moderate psoriasis with blood-heat syndrome, but there is a lack of evidence-based medical evidence. This trial aims to evaluate the efficacy and safety of LJR ointment for the treatment of mild and moderate psoriasis with blood-heat syndrome. Methods: A multicenter, randomized, double-blind, placebo-controlled, and self-controlled clinical trial was carried out according to this paper. The symmetrical rashes of each subject were regarded as the target lesions and were randomly divided into a treatment group (LJR ointment group) and a control group (placebo group). The LJR ointment or placebo ointment were externally administered on bilateral symmetric rashes, twice a day for eight weeks. The follow-up examination was made for subjects every two weeks. The primary research finding was conveyed by Psoriasis Area and Severity Index (PASI) in 8 weeks. The secondary research finding includes adverse events. Results: 46 subjects undergo this research project. The difference between PASI scores of the target lesions in the treatment group and control group is statistically significant were in 8 weeks (P < .001). The percentage of PASI 75 in treatment group and control group were 48% and 15% in week 8, respectively (x2 = 11.33, P < .05). No severe adverse events were reported. Conclusions: LJR ointment was proved to have efficacy in the treatment of mild and moderate psoriasis with the blood-heat syndrome.

[1]  M. Fontes,et al.  Inflammasome NLRP3 activation induced by Convulxin, a C-type lectin-like isolated from Crotalus durissus terrificus snake venom , 2022, Scientific Reports.

[2]  Jorddy Neves Cruz,et al.  Antiproliferative, genotoxic activities and quantification of extracts and cucurbitacin B obtained from Luffa operculata (L.) Cogn , 2021, Arabian Journal of Chemistry.

[3]  L. March,et al.  Skin Barrier Dysregulation in Psoriasis , 2021, International journal of molecular sciences.

[4]  E. Andrade,et al.  In silico analyses of toxicity of the major constituents of essential oils from two Ipomoea L. species. , 2021, Toxicon : official journal of the International Society on Toxinology.

[5]  R. Burbano,et al.  Evaluation of the genotoxicity and mutagenicity of isoeleutherin and eleutherin isolated from Eleutherine plicata herb. using bioassays and in silico approaches , 2021 .

[6]  Yan Wang,et al.  Indirubin attenuates IL-17A-induced CCL20 expression and production in keratinocytes through repressing TAK1 signaling pathway. , 2021, International immunopharmacology.

[7]  T. Montero-Vílchez,et al.  Skin Barrier Function in Psoriasis and Atopic Dermatitis: Transepidermal Water Loss and Temperature as Useful Tools to Assess Disease Severity , 2021, Journal of clinical medicine.

[8]  Ping Wang,et al.  Effectiveness of flesh-moistening paste in psoriasis vulgaris patients with symptom pattern of blood stasis: a randomized and parallel-controlled trial. , 2020, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.

[9]  C. Taft,et al.  Novel chalcones derivatives with potential antineoplastic activity investigated by docking and molecular dynamics simulations , 2020, Journal of biomolecular structure & dynamics.

[10]  E. Gonçalves,et al.  In silico improvement of the cyanobacterial lectin microvirin and mannose interaction , 2020, Journal of biomolecular structure & dynamics.

[11]  X. Hou,et al.  Novel Chinese Angelica Polysaccharide Biomimetic Nanomedicine to Curcumin Delivery for Hepatocellular Carcinoma Treatment and Immunomodulatory Effect. , 2020, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[12]  Yuanyuan Xu,et al.  Shikonin inhibits CEBPD downregulation in IL-17-treated HaCaT cells and in an imiquimod-induced psoriasis model , 2020, Molecular Medicine Reports.

[13]  R. Giesey,et al.  The global, regional, and national burden of psoriasis in 195 countries and territories, 1990-2017: A systematic analysis from the Global Burden of Disease Study 2017. , 2020, Journal of the American Academy of Dermatology.

[14]  Wenxia Lin,et al.  To explore the clinical efficacy of Traditional Chinese Medicine bath in the treatment of psoriasis vulgaris with blood-heat syndrome and its effect on related cytokines based on different temperature and different concentration , 2020, Medicine.

[15]  M. J. Hashim,et al.  Global burden of psoriasis – comparison of regional and global epidemiology, 1990 to 2017 , 2020, International journal of dermatology.

[16]  Jianpin Liu,et al.  Effect of Traditional Chinese Medicine plus narrow-band medium-wave ultraviolet B radiation on moderate-to-severe psoriasis vulgaris in a case series. , 2019, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.

[17]  L. Matza,et al.  Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI) , 2019, Journal of medical economics.

[18]  J. S. C. Araújo,et al.  In Silico Study to Identify New Antituberculosis Molecules from Natural Sources by Hierarchical Virtual Screening and Molecular Dynamics Simulations , 2019, Pharmaceuticals.

[19]  Yoko Koga,et al.  Anti‐IL‐12/IL‐23p40 antibody ameliorates dermatitis and skin barrier dysfunction in mice with imiquimod‐induced psoriasis‐like dermatitis , 2018, European journal of pharmacology.

[20]  P. Bigliardi.  Role of Skin pH in Psoriasis. , 2018, Current problems in dermatology.

[21]  Jianpin Liu,et al.  Chinese herbal Pulian ointment in treating psoriasis vulgaris of blood-heat syndrome: a multi-center, double-blind, randomized, placebo-controlled trial , 2017, BMC Complementary and Alternative Medicine.

[22]  David Moher,et al.  CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement. , 2016, Journal of clinical epidemiology.

[23]  Yang Zhao,et al.  Evaluating the economic burden of psoriasis in the United States. , 2015, Journal of the American Academy of Dermatology.

[24]  P. Elias,et al.  Abnormal Epidermal Barrier Recovery in Uninvolved Skin supports the Notion of an Epidermal Pathogenesis of Psoriasis , 2014, The Journal of investigative dermatology.

[25]  M. Cork,et al.  Topical Treatments for Chronic Plaque Psoriasis of the Scalp: a Systematic Review Running head: Topical Treatments for Chronic Plaque Psoriasis of the Scalp , 2017 .

[26]  Yin-ku Lin,et al.  Indirubin, an acting component of indigo naturalis, inhibits EGFR activation and EGF-induced CDC25B gene expression in epidermal keratinocytes. , 2012, Journal of dermatological science.

[27]  G. Leone,et al.  Evaluation of a skin protection cream for dry skin in patients undergoing narrow band UVB phototherapy for psoriasis vulgaris. , 2011, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.

[28]  W. Bollag,et al.  Abnormal aquaporin-3 protein expression in hyperproliferative skin disorders , 2011, Archives of Dermatological Research.

[29]  A. Atanasov,et al.  Indirubin-3′-Monoxime Blocks Vascular Smooth Muscle Cell Proliferation by Inhibition of Signal Transducer and Activator of Transcription 3 Signaling and Reduces Neointima Formation In Vivo , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[30]  Dingquan Yang,et al.  Effect of Chinese herbal medicine combined with acitretin capsule in treating psoriasis of blood-heat syndrome type , 2009, Chinese journal of integrative medicine.

[31]  Shu-Chen Chang,et al.  Clinical assessment of patients with recalcitrant psoriasis in a randomized, observer-blind, vehicle-controlled trial using indigo naturalis. , 2008, Archives of dermatology.

[32]  Duan De-jian.  The Influence of Angelica Polysaccharide on the Expression Levels of PCNA in Psoriasis-like Lesions of Guinea Pigs , 2008 .

[33]  A S Verkman,et al.  Aquaporin‐3 functions as a glycerol transporter in mammalian skin , 2005, Biology of the cell.

[34]  Mark Lebwohl,et al.  Psoriasis , 1906, The Lancet.

[35]  G L Snyder,et al.  Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? , 2001, The Journal of biological chemistry.

[36]  Griffiths,et al.  Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality , 1999, The British journal of dermatology.

[37]  Doris Marko,et al.  Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases , 1999, Nature Cell Biology.

[38]  I. Liao,et al.  ARTICLE: Evolution of Skin Barrier Science for Healthy and Compromised Skin , 2022, Journal of Drugs in Dermatology.